The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases

Current Opinion in Rheumatology

Volumn 27, Issue 1, 2015, Pages 71-75

  Sherlock, Jonathan P ^a,c   Taylor, Peter C ^a,b   Buckley, Christopher D ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Interleukin 17; Interleukin 23; Rheumatoid arthritis; Spondyloarthropathy; Systemic lupus erythematosus

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 17; INTERLEUKIN 23; TOCILIZUMAB; IMMUNOLOGIC FACTOR;

AORTITIS; BONE EROSION; HUMAN; OSSIFICATION; PERIOSTITIS; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; RHEUMATIC DISEASES;

HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INTERLEUKIN-17; INTERLEUKIN-23; RHEUMATIC DISEASES;

EID: 84918523128     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000132     Document Type: Review

References (53)

1. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. Nat Rev Immunol 2014; 14:585- 600.
2. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011; 162:785-791.
3. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- And antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198:1951-1957.
4. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60:1647-1656.
5. Pène J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008; 180: 7423-7430.
6. Gullick NJ, Evans HG, Church LD, et al. Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint. PLoS One 2010; 5:e12516.
7. Ziolkowska M, Koc A, Luszczykiewicz G, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000; 164:2832-2838.
8. Suurmond J, Dorjée AL, Boon MR, et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 2011; 13:R150.
9. Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3 T cells into TH17 cells in autoimmune arthritis. Nat Med 2014; 20:62-68.
10. Samson M, Audia S, Janikashvili N, et al. Brief report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64:2499-2503.
11. Moran EM, Mullan R, McCormick J, et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther 2009; 11:R113.
12. Chen L, Wei X-Q, Evans B, et al. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol 2008; 38:2845-2854.
13. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203:2673-2682.
14. Li X, Kim K-W, Cho M-L, et al. IL-23 induces receptor activator of NF-kappaB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-kappaB signal pathways. Immunol Lett 2010; 127:100-107.
15. Ju J-H, Cho M-L, Moon Y-M, et al. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4 T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 2008; 181:1507-1518.
16. Pickens SR, Volin MV, Mandelin AM, et al. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010; 184:3233-3241.
17. Alzabin S, Abraham SM, Taher TE, et al. Incomplete response of inflammatory arthritis to TNFa blockade is associated with the Th17 pathway. Ann Rheum Dis 2012; 71:1741-1748.
18. Genovese MC, Greenwald M, Cho C-S, et al. A phase II randomized study of subcutaneous ixekizumab, an antiinterleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014; 66:1693-1704.
19. Chen DY, Chen YM, Wen MC, et al. The potential role of Th17 cells and Th17- related cytokines in the pathogenesis of lupus nephritis. Lupus 2012; 21:1385-1396.
20. Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4 T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989; 143:103-112.
21. Crispín JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181:8761-8766.
22. Wang Y, Ito S, Chino Y, et al. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol 2010; 159:1-10.
23. Pisitkun P, Ha H-L, Wang H, et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012; 37:1104- 1115.
24. Du J, Li Z, Shi J, Bi L. Associations between serum interleukin-23 levels and clinical characteristics in patients with systemic lupus erythematosus. J Int Med Res 2014; 42:1123-1130.
25. Rana A, Minz RW, Aggarwal R, et al. Gene expression of cytokines (TNF-a, IFN-g), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 2012; 21:1105-1112.
26. Smith S, Gabhann JN, Higgs R, et al. Enhanced interferon regulatory factor 3 binding to the interleukin-23p19 promoter correlates with enhanced interleukin-23 expression in systemic lupus erythematosus. Arthritis Rheum 2012; 64:1601-1609.
27. Puwipirom H, Hirankarn N, Sodsai P, et al. Increased interleukin-23 receptor() T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Arthritis Res Ther 2010; 12:R215.
28. Mok MY, Wu HJ, Lo Y, Lau CS. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol 2010; 37:2046-2052.
29. Yang X-Y, Wang H-Y, Zhao X-Y, et al. Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus. J Clin Immunol 2013; 33:767-774.
30. Vincent FB, Northcott M, Hoi A, et al. Clinical associations of serum interleukin- 17 in systemic lupus erythematosus. Arthritis Res Ther 2013; 15:R97.
31. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009; 183:3160-3169.
32. Kyttaris VC, Zhang Z, Kuchroo VK, et al. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol 2010; 184:4605-4609.
33. Kyttaris VC, Kampagianni O, Tsokos GC. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. Biomed Res Int 2013; 2013:861028.
34. Espinosa A, Dardalhon V, Brauner S, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by dysregulating the IL-23-Th17 pathway. J Exp Med 2009; 206:1661-1671.
35. Yao L, Chen H-P, Ma Q. Piperlongumine alleviates lupus nephritis in MRLFas( lpr) mice by regulating the frequency of Th17 and regulatory T cells. Immunol Lett 2014; 161:76-80.
36. Wen Z, Xu L, Xu W, Xiong S. Detection of dynamic frequencies of Th17 cells and their associations with clinical parameters in patients with systemic lupus erythematosus receiving standard therapy. Clin Rheumatol 2014; 33:1451- 1458.
37. Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC). Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39:1329-1337.
38. Duerr R, Taylor K, Brant S, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461- 1463.
39. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122:201-206.
40. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80:273-290.
41. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41:199- 204.
42. Tonel G, Conrad C, Laggner U, et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol 2010; 185:5688-5691.
43. Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176:1908-1915.
44. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199:125-130.
45. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995; 22:2273-2278.
46. Ciccia F, Bombardieri M, Principato A, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009; 60:955-965.
47. Colbert RA, DeLay ML, Klenk EI, Layh-Schmitt G. From HLA-B27 to spondyloarthritis: A journey through the ER. Immunol Rev 2010; 233:181-202.
48. Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2 and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011; 186:2672-2680.
49. Goodall JC, Wu C, Zhang Y, et al. Endoplasmic reticulum stress-induced transcription factor, CHOP, is crucial for dendritic cell IL-23 expression. Proc Natl Acad Sci U S A 2010; 107:17698-17703.
50. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gt CD3CD4-CD8- entheseal resident T cells. Nat Med 2012; 18:1069-1076.
51. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780-789.
52. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological antitumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73:990-999.
53. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13:715-725.